<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02690961</url>
  </required_header>
  <id_info>
    <org_study_id>HR-KB103</org_study_id>
    <secondary_id>ChiCTR-TRC-14005111</secondary_id>
    <nct_id>NCT02690961</nct_id>
  </id_info>
  <brief_title>Study of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers</brief_title>
  <official_title>Randomized, Double-blind Placebo-controlled Phase I Study to Assess Safety, Tolerance，Pharmacokinetics of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Chasesun Pharmaceutical Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Chasesun Pharmaceutical Co., LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety, tolerance and pharmacokinetics of
      Multiple-dose Kukoamine B Mesilate in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">June 14, 2016</completion_date>
  <primary_completion_date type="Actual">June 14, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events.</measure>
    <time_frame>14 days</time_frame>
    <description>adverse event, physical examination, monitoring of vital signs, Laboratory examination, electrocardiogram(ECG).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters(Maximum Plasma Concentration [Cmax])</measure>
    <time_frame>the first day,the sixth day(before the three injections from bottom),the seventh day</time_frame>
    <description>before the first injecting(omin); after starting the first injecting 30min;ending the first injecting instantly,1h,3h,6h,8h,12h,16h,23h;before the three injections from bottom,after starting the last injecting 30min,ending the last injecting instantly,1h,3h,6h,8h,12h,16h,23h.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters(Area Under Curve [AUC])</measure>
    <time_frame>the first day,the sixth day(before the three injections from bottom),the seventh day</time_frame>
    <description>before the first injecting(omin); after starting the first injecting 30min;ending the first injecting instantly,1h,3h,6h,8h,12h,16h,23h;before the three injections from bottom,after starting the last injecting 30min,ending the last injecting instantly,1h,3h,6h,8h,12h,16h,23h.</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Kukoamine B Mesilate 0.06mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: Kukoamine B Mesilate 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kukoamine B Mesilate 0.12mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: Kukoamine B Mesilate 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kukoamine B Mesilate 0.24mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: Kukoamine B Mesilate 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 0.06mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: placebo 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 0.12mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: placebo 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 0.24mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: placebo 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kukoamine B Mesilate</intervention_name>
    <description>Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.</description>
    <arm_group_label>Kukoamine B Mesilate 0.06mg/kg</arm_group_label>
    <arm_group_label>Kukoamine B Mesilate 0.12mg/kg</arm_group_label>
    <arm_group_label>Kukoamine B Mesilate 0.24mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo multiple doses</intervention_name>
    <arm_group_label>Placebo 0.06mg/kg</arm_group_label>
    <arm_group_label>Placebo 0.12mg/kg</arm_group_label>
    <arm_group_label>Placebo 0.24mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Gender: male or female, each sex ratio does not exceed 2/3;

          2. 18-45 years (including upper and lower limit), the general situation is good;

          3. Body mass index (BMI) in 19-28 (including upper and lower limit of the range),
             bodyweight（BW）≥ 50kg (female) and 60kg (male);

          4. Nearly half of the year, no child care program and agreed to take effective measures
             to contraception during the study period, women of childbearing age blood pregnancy
             test was negative;

          5. Subjects to fully understand the purpose, properties, method and reactions may occur
             of test drug trials.Voluntarily signed the informed consents, and agreed to abide by
             the requirements of clinical protocols.

        Exclusion Criteria:

          1. Primary disease in important organs;

          2. Mental or physical disability;

          3. Familial hereditary disease;

          4. Screening supine blood pressure (after 5 minutes of rest) systolic or diastolic blood
             pressure greater than 90-140 millimeters of mercury(mmHg), beyond the scope of 50-90
             millimeters of mercury(mmHg), Or pulse (HR) beyond 50bpm-100bpm;

          5. Abnormal results of any clinically meaningful physical examination, vital signs, ECG
             or clinical laboratory;

          6. History of immunodeficiency diseases, including HIV antibody positive;

          7. Detection of antibody positive, hepatitis B surface antigen or antibody to hepatitis C
             / syphilis positive;

          8. Alcohol and drug abusers;

          9. Who is addicted to alcohol and tobacco (drinking 14 units of alcohol per week: 1 unit
             = beer 285 ml, or liquor 25 ml, or wine 1 cup. numbers of daily smoking ≥ 5) and / or
             not smoking and drinking in the test period;

         10. Any discharge period may affect the study drug, or in the past 3 months participated
             in any drug clinical trials;

         11. Before entering the group 4 weeks using any prescription drugs before entering the
             group, or use of any non prescription drugs within 2 weeks (vitamins, herbal tonics,
             etc.), or into the group within 2 weeks before taking effect of drug metabolizing
             enzymes in food, such as grapefruit or grapefruit drink. Can the use of acetaminophen,
             but must record report in case report form（CRF）;

         12. The last 3 months had a history of blood donation or significant blood loss (more than
             400ml);

         13. There are drugs, the clinical significance of the history of food allergy and atopic
             allergic diseases (asthma, urticaria, eczema dermatitis) or a known drug to test drugs
             or similar drug allergy test;

         14. Lactating women, pregnant women or unable to take effective contraceptive measures;

         15. Researchers believe that participants not suitable to take the test for other factors
             .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuai Chen</last_name>
    <role>Study Director</role>
    <affiliation>Tianjin Chasesun Pharmaceutical Co., LTD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>BeiJing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

